TY - JOUR

T1 - Health and quality of life of patients with haemophilia

T2 - A national study of 124 Danish men

AU - Schnohr, Christina

AU - Ekholm, Ola

AU - Poulsen, Lone Hvitfeldt

AU - Lehrmann, Lars

AU - Andersen, Terkel

AU - Funding, Eva

AU - Holm, Karen Binger

AU - Bjorner, Jakob Bue

N1 - Publisher Copyright: © 2023 The Authors. Haemophilia published by John Wiley & Sons Ltd.

PY - 2023

Y1 - 2023

N2 - Purpose: In the past decades, haemophilia treatment has greatly improved the health of persons with haemophilia (PWH). This study compares PWH to the general population on social conditions and health. Methods: In December 2021, all Danes with moderate or severe haemophilia A or B, or von Willebrands disease type 3 were invited to participate in an online self-report survey concerning sociodemographic factors, self-rated health, teeth status, chronic health conditions, symptoms and loneliness. This study compares responses from the 124 adult male PWH with responses from a male general population sample (N = 4849). Analyses used logistic regression, controlling for age and highest completed education. Results: Fewer PWH were in the oldest age group (65-84 years). Controlling for age, no significant differences were found regarding cohabitation status or education. Fewer PWH were employed (OR =.48, [.33-.71])—particularly in the 45–64 age group. PWH were less likely to report good health (OR =.49, [.31-.77]). The odds of joint disease was much higher (OR = 13.00, [8.37-20.28]). Also, hypertension (OR = 2.25, [1.13-5.65]) and previous stroke (OR = 2.51, [1.44-3.50]) were more frequent. PWH were more likely to report pain in the arms/hands/legs/hips (OR = 2.94, [1.92-4.52]), but less likely to report pain in the head/neck/shoulder (OR =.66, [.45-.96]). Conclusion: The disease burden of haemophilia has improved so PWH resembles the general population in areas such as marriage and education. However, even for young PWH, the disease still imposes a significant burden from hemophilia arthropathy and pain in extremities and joints. Middle-aged PWH also have poorer levels of employment than same-aged peers.

AB - Purpose: In the past decades, haemophilia treatment has greatly improved the health of persons with haemophilia (PWH). This study compares PWH to the general population on social conditions and health. Methods: In December 2021, all Danes with moderate or severe haemophilia A or B, or von Willebrands disease type 3 were invited to participate in an online self-report survey concerning sociodemographic factors, self-rated health, teeth status, chronic health conditions, symptoms and loneliness. This study compares responses from the 124 adult male PWH with responses from a male general population sample (N = 4849). Analyses used logistic regression, controlling for age and highest completed education. Results: Fewer PWH were in the oldest age group (65-84 years). Controlling for age, no significant differences were found regarding cohabitation status or education. Fewer PWH were employed (OR =.48, [.33-.71])—particularly in the 45–64 age group. PWH were less likely to report good health (OR =.49, [.31-.77]). The odds of joint disease was much higher (OR = 13.00, [8.37-20.28]). Also, hypertension (OR = 2.25, [1.13-5.65]) and previous stroke (OR = 2.51, [1.44-3.50]) were more frequent. PWH were more likely to report pain in the arms/hands/legs/hips (OR = 2.94, [1.92-4.52]), but less likely to report pain in the head/neck/shoulder (OR =.66, [.45-.96]). Conclusion: The disease burden of haemophilia has improved so PWH resembles the general population in areas such as marriage and education. However, even for young PWH, the disease still imposes a significant burden from hemophilia arthropathy and pain in extremities and joints. Middle-aged PWH also have poorer levels of employment than same-aged peers.

KW - haemophilia

KW - quality of life

KW - questionnaire

U2 - 10.1111/hae.14751

DO - 10.1111/hae.14751

M3 - Journal article

C2 - 36729615

AN - SCOPUS:85147430799

VL - 29

SP - 538

EP - 544

JO - Haemophilia, Supplement

JF - Haemophilia, Supplement

SN - 1355-0691

IS - 2

ER -